Missed a Tirzepatide Dose? The 4-Day Rule Explained

Tirzepatide is a once-weekly research compound, which means the schedule has built-in slack. If you forget a dose, you are not automatically back to square one. The general reference framework most protocols point to is a 96-hour window: roughly four days from your normal injection time in which the missed dose can still be taken on the same weekly track.

This article walks through the math of that window, why doubling up is never part of the picture, and how a longer gap of two weeks or more changes the picture entirely. This is educational reference information only, not dosing guidance. Any real decision belongs with a licensed clinician, and you can model your own vial numbers with the tirzepatide calculator.

The 4-day (96-hour) rule

The common reference rule works like this. Count the hours since your scheduled injection time. If you are inside about 96 hours, the standard guidance is to take the missed dose, then keep your original weekly day. If more than 96 hours have passed, the typical reference is to skip the missed dose entirely and resume on your next regular day.

• Within 96 hours of the scheduled time: take the missed dose, keep the same weekly day
• More than 96 hours past: skip it, wait for the next scheduled day
• Either way, the next dose stays on your original weekly anchor day

A worked example makes it concrete. Say your injection day is Sunday morning at 8 a.m. You forget. By Wednesday at 8 a.m. only 72 hours have passed, which is inside the window, so the reference is to take it Wednesday and still inject again the following Sunday. But if you do not remember until Thursday at noon, that is past 96 hours, so the common guidance is to skip and resume the next Sunday.

Why you never double up

The most important rule here is also the simplest. You do not add a missed dose on top of your next scheduled dose to make up the gap. Taking two weekly doses close together stacks the compound far above the intended weekly level, and the most reported issue with GLP-1 and GIP compounds at higher exposure is gastrointestinal: nausea, vomiting, and similar effects covered in our GLP-1 side effects guide.

The general reference is that two doses should always be separated by at least 3 days (72 hours). So even when you take a missed dose inside the 96-hour window, the next scheduled dose may need to shift so it does not land within 72 hours of the catch-up dose. The spacing rule and the 4-day rule work together.

Example: your day is Sunday, you miss it, and you take the dose on the following Friday (about 120 hours, so already past the window in most references). If you then injected again on Sunday, that is only 2 days apart, which breaks the 3-day minimum. That is exactly the scenario the rules are designed to avoid.

After 2 weeks off: the dose resets

A single missed week is a timing question. A gap of two weeks or more is a different question, because tolerance fades. Tirzepatide titration schedules step the dose up slowly for a reason, and the general reference is that going more than 2 weeks without a dose may mean restarting at a lower step rather than resuming the higher dose you were on.

• Missed 1 week: timing problem, governed by the 96-hour and 72-hour rules above
• Missed 2 or more consecutive weeks: tolerance question, often a restart at a lower titration step
• The restart point is a clinical decision, not a fixed formula

Why lower? The same dose that felt fine before a long gap can feel like a fresh jump afterward, and the reported side-effect load tends to track how fast the body sees the compound relative to recent exposure. The tirzepatide dosage chart lays out the standard step sequence so you can see where a restart might land. A clinician decides the actual number.

Run your own numbers

Whatever dose you resume at, the volume you draw depends on how the vial was reconstituted, not just the milligrams. A 2.5 mg dose can sit at 25 units or 50 units on the same syringe depending on concentration, so a catch-up or restart dose still needs to be converted from mg to units for your specific vial.

1. Confirm your vial strength in mg and how much bacteriostatic water was added
2. Find concentration: mg in the vial divided by mL of water
3. Convert your target dose to units with the tirzepatide calculator
4. Cross-check the result against the tirzepatide units chart

The rules above are widely cited reference points, not a personal protocol. Tirzepatide is a research compound not approved for human consumption, and none of this is medical advice. Take any timing or restart question to a licensed clinician, and see our disclaimer for the full picture.